Table 3

Clinical data for the five patients with a long delay between the onset of the neuropathy and the discovery of the tumour who had no anti-onconeural antibodies (group IIB)

NoSex/ageDelay (y)Clinical manifestationsCourseRankinElectrophysiologyCSFTumourPathological study
222M/735Sensory loss in lower limbs, lower limbs areflexiaProgressive2 Axonal, reduced/absent SAP, reduced MAP, mild reduction of CV0.8 g/l 1 lymphoProstate adenocarcinomaNerve biopsy: fibre loss, no inflammatory changes
23F/719Pain, paresthesia, sensory loss and areflexia in lower limbsProgressive1 Axonal, reduced MAP/SAP. Mild reduction of CV0.2 g/l 1 lymphoPancreas adenocarcinomaFibre loss, regenerating clusters, no inflammatory changes
24M/724-5Distal sensory motor deficit and areflexia in lower limbsProgressive2 Axonal, reduced/absent SAP and MAP, mild reduction M-S CV0.67 g/l 1 lymphoPenis epitheliomaNerve biopsy: severe fibre loss, no inflammatory changes
25M/6414Sensory motor distal deficit and areflexia in lower limbs Progressive2 Axonal, reduced MAP/SAP, mild reduction of CV0.7 g/l 1 lymphoProstate adenocarcinomaND
26M/6410CIDP. Mild paraesthesia and motor deficit, hyporeflexia in four limbs. Hypertrophic nerves. MGUS IgGProgressive1 Demyelinating severely reduced MCV, temporal dispersion8.2 g/l 1 lymphoMalignant melanomaNerve biopsy: demyelinated fibres, onion bulb formations
  • Abbreviations are the same as in table 2. In all cases, the neuropathy preceded the diagnosis of cancer.